Notes
costs and QALYs were discounted at 3.5% per annum
Reference
Tsochatzis EA, et al. Cost-effectiveness of non-invasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology : 4 Jul 2014. Available from: URL: http://doi.org/10.1002/hep.27296
Rights and permissions
About this article
Cite this article
Treat all without testing strategy best bet for CHC in UK. PharmacoEcon Outcomes News 709, 9 (2014). https://doi.org/10.1007/s40274-014-1463-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1463-1